499 F.3d 1293 (Fed. Cir. 2007), 2006-1530, Aventis Pharma Deutschland GmbH v. Lupin, Ltd.

Citation: 499 F.3d 1293, 84 U.S.P.Q.2d 1197

Party Name: AVENTIS PHARMA DEUTSCHLAND GmbH, Plaintiff-Cross Appellant, and King Pharmaceuticals, Inc., Plaintiff-Cross Appellant, v. LUPIN, LTD. and Lupin Pharmaceuticals, Inc., Defendants-Appellants.

Case Date: September 11, 2007

Court: U.S. Court of Appeals — Federal Circuit

Linked as:

Document options

Printable page
Email this

Extract

499 F.3d 1293 (Fed. Cir. 2007), 2006-1530, Aventis Pharma Deutschland GmbH v. Lupin, Ltd.

No longer available (Autolink)

See the full content of this document

This document cites

US Code - 35 U.S.C. § 102 Conditions For Patentability; Novelty
US Code - 35 U.S.C. § 103 Conditions For Patentability; Non-Obvious Subject Matter
US Code - 35 U.S.C. § 120 Benefit of Earlier Filing Date In the United States
US Code - 35 U.S.C. § 271 Infringement of Patent
US Code - 28 U.S.C. § 1295 Jurisdiction of the United States Court of Appeals For the Federal Circuit

See all quotations